Showing 1 - 6 results of 6 for search 'Jacquelyn A. Hank', query time: 0.03s Refine Results
  1. 1
    NK cell mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

    NK cell mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy by Wei eWang, Amy K. Erbe, Jacquelyn A. Hank, Zachary S. Morris, Paul Mark Sondel, Paul Mark Sondel

    Published 2015-07-01
    Get full text
    Article
  2. 2
    Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines

    Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines by Zulmarie Perez Horta, Swetha Saseedhar, Alexander L. Rakhmilevich, Lakeesha Carmichael, Jacquelyn A. Hank, Margaret Boyden, Stephen D. Gillies, Paul M. Sondel

    Published 2019-06-01
    Get full text
    Article
  3. 3
    A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors

    A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors by Michael W. Bishop, Paul R. Hutson, Jacquelyn A. Hank, Paul M. Sondel, Wayne L. Furman, Michael M. Meagher, Fariba Navid, Victor M. Santana

    Published 2020-01-01
    Get full text
    Article
  4. 4
    Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome observed in high-risk neuroblastoma

    Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome observed in high-risk neuroblastoma by Tony A. Koehn, Lori L. Scardino, Kory L. Alderson, Amy K. Erbe, Kim A. McDowell, Bartosz eGrzywacz, Jacquelyn A. Hank, Paul Mark Sondel

    Published 2012-05-01
    Get full text
    Article
  5. 5
    Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

    Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab by Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl, Paul M. Sondel

    Published 2019-03-01
    Get full text
    Article
  6. 6
    HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy

    HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy by Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Alice L. Yu, Paul M. Sondel, Paul M. Sondel

    Published 2017-06-01
    Get full text
    Article

Search Tools: